News
Wed, 07 May 2025 05:15:00 -0400
Wed, 07 May 2025 05:15:00 -0400
Financial report for the period 1 January 2025 to 31 March 2025
|
PROFIT AND LOSS |
Q1 2025 |
Q1 2024 |
Growth as reported |
Growth at CER* |
|
USD million |
|
|
|
|
|
Net sales |
11,012 2,087 |
9,349 |
19% |
18% |
|
Operating profit |
5,470 |
4,638 |
22% |
20% |
|
|
|
|
|
|
|
Net profit |
4,0944 |
3,700 |
14% |
N/A |
|
Diluted earnings per share (in USD) |
0.92 |
0.83 |
15% |
N/A |
|
* CER: Constant exchange rates (average 2024). |
||||
|
** For convenience, Danish Kroner has been translated to USD in this release, using the average exchange rates of USD 1.0 = DKK 7.09128 and the period-end exchange rate of USD 1.0 = DKK 6.89903 |
||||
Lars Fruergaard Jørgensen, president and CEO: "In the first quarter of 2025, we delivered 18% sales growth and continued to expand the reach of our innovative GLP-1 treatments. However, we have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the US. We are actively focused on preventing unlawful and unsafe compounding and on efforts to expand patient access to our GLP-1 treatments. Within R&D, we are pleased to have completed the last pivotal trial for our next-generation obesity treatment, CagriSema, and to have filed for US approval of oral semaglutide 25 mg, with the potential to be the first oral GLP-1 treatment for obesity."
On 7 May 2025 at 13.00 CET, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under 'Investors' (the contents of the company's website do not form a part of this Form 6-K).